Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 9/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 4/20 | 0.40 |
| ▸ | MC4R | P32245 | 2/20 | 0.40 |
| ▸ | MC3R | P41968 | 2/20 | 0.40 |
| ▸ | MC1R | Q01726 | 2/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL592840 | 0.88 | DPP4 (0.41) | TACR1DPP4DPP8DPP9DPP7 | |
| SCHEMBL592356 | 0.83 | NR1H2 (0.48) | TACR1DPP4 | |
| SCHEMBL18862951 | 0.81 | HSD11B1 (0.48) | HSD11B1MC4RMC3RMC1RABCB1 | |
| SCHEMBL18862950 | 0.81 | HSD11B1 (0.48) | HSD11B1MC4RMC3RMC1RABCB1 | |
| SCHEMBL13722390 | 0.80 | TACR1 (0.46) | TACR1HSD11B1MC4RMC3RMC1R | |
| SCHEMBL29187960 | 0.80 | TACR1 (0.52) | TACR1HSD11B1MC4RMC3RMC1R | |
| SCHEMBL28169013 | 0.80 | TACR3 (0.50) | — | |
| SCHEMBL7854892 | 0.79 | TACR1 (0.63) | TACR1HSD11B1DPP4MC4RMC3R | |
| SCHEMBL6952343 | 0.79 | L3MBTL1 (0.49) | TACR1HSD11B1MC4RMC3RMC1R | |
| SCHEMBL29270706 | 0.79 | TACR1 (0.47) | TACR1HSD11B1MC4RMC3RMC1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8415378-B2 | Isoxazol-3(2H)-one analogs as therapeutic agents | ASTRAZENECA AB (SE) | 2013-04-09 | — | — | US | disclosed |
| US-20100261755-A1 | ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2010-10-14 | — | — | US | disclosed |
| WO-2006086609-A2 | INHIBITORS OF TRYPTASE | AXYS PHARMACEUTICALS, INC. (US) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261755-A1 | ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS | NR4A3, CBR3, OXER1 | TACR1 474/4885HSD11B1 1197/4885DPP4 754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.